Keywords: Takeda, Nesina, Pricinf, Japan, Furiex, Milestone
Takeda receives pricing approval of Nesina in Japan, triggering milestone for Furiex Pharma
Article | 14 June 2010
Japan’s largest drugmaker Takeda Pharmaceutical received pricing approval for its type 2 diabetes drug Nesina (alogliptin), a highly selective DPP-4, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
